ERBB2 and neoplasm: The expression of PD1 in the tumor microenvironment is a mechanism of tumor evasion, the combination of anti-HER2 monoclonal antibodies with anti-PD1 is synergic, improving therapeutic activity, reason why these combinations are being tested in different trials [123].